Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma

Mary Ann Comunale1, Lucy Rodemich-Betesh1, Julie Hafner1, Mengjun Wang1, Pamela Norton1, Adrian M. Di Bisceglie2, Timothy Block1, Anand Mehta1*

1 Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, Pennsylvania, United States of America. 2 Division of Gastroenterology and Hepatology, Saint Louis VA Medical Center, Saint Louis University School of Medicine, St Louis, Missouri, United States of America

Abstract

Background: We previously reported increased levels of protein-linked fucosylation with the development of liver cancer and identified many of the proteins containing the altered glycan structures. One such protein is alpha-1-antitrypsin (A1AT). To advance these studies, we performed N-linked glycan analysis on the five major isoforms of A1AT and completed a comprehensive study of the glycosylation of A1AT found in healthy controls, patients with hepatitis C (HCV) induced liver cirrhosis, and in patients infected with HCV with a diagnosis of hepatocellular carcinoma (HCC).

Methodology/Principal Findings: Patients with liver cirrhosis and liver cancer had increased levels of triantennary glycan-containing outer arm (α-1,3) fucosylation. Increases in core (α-1,6) fucosylation were observed only on A1AT from patients with cancer. We performed a lectin fluorophore-linked immunosorbent assay using Aleuria Aurantia lectin (AAL), specific for core and outer arm fucosylation in over 400 patients with liver disease. AAL-reactive A1AT was able to detect HCC with a sensitivity of 70% and a specificity of 86%, which was greater than that observed with the current marker of HCC, alpha-fetoprotein. Glycosylation analysis of the false positives was performed; results indicated that these patients had increases in outer arm fucosylation but not in core fucosylation, suggesting that core fucosylation is cancer specific.

Conclusions/Significance: This report details the stepwise change in the glycosylation of A1AT with the progression from liver cirrhosis to cancer and identifies core fucosylation on A1AT as an HCC specific modification.

Introduction

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is the major etiology of hepatocellular cancer (HCC) [1–4]. Both HBV and HCV cause acute and chronic liver infections, and most chronically infected individuals remain asymptomatic for many years [3]. About 10% to 40% of all chronic HBV carriers eventually develop liver cancer, and it is estimated that over one million people worldwide die because of HBV- and HCV-associated liver cancer [2,6,7]. Indeed, HBV and HCV infections are associated with over 80% of all cases of HCC worldwide and can be as high as 96% in regions where HBV is endemic [3].

The progression of liver disease to liver cancer is primarily monitored by serum levels of the oncofetal glycoprotein, alpha-fetoprotein (AFP), or the core fucosylated glycoform of AFP, AFP-L3. AFP can, however, be produced in many circumstances, including in relation to other liver diseases [8–10] and is not present in all those with HCC [11]. Therefore the use of AFP as a primary screen for HCC has been questioned [12], and more sensitive serum biomarkers for HCC are needed.

The glycosylation of proteins is cell specific. The N-linked glycosylation of a protein reflects modifications that occurred in the cell from which it came [13]. The glycosylation of the same protein secreted from diseased tissue, malignant cells or normal cells may, and often do, differ [14]. We, and others, have observed changes in N-linked glycosylation with the development of cirrhosis and HCC [15–19]. Specifically, the amount of core fucosylated N-linked glycan derived from total protein preparations isolated from the serum of individuals chronically infected with HCV and from those with a diagnosis of HCC was consistently greater than that in healthy patients or in those with HCV and “inactive” disease [19].

Using fucose-specific lectins to identify the proteins that become fucosylated in patients with liver disease, we identified more than 100 glycoproteins from patients with HCC and/or cirrhosis that contained increased fucosylation [19]. One of these proteins was

Citation: Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P. et al. (2010) Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma. PLoS ONE 5(8): e12419. doi:10.1371/journal.pone.0012419

Editor: Wang-Shick Ryu, Yonsei University, Republic of Korea

Received: June 15, 2010; Accepted: July 22, 2010; Published: August 25, 2010

Copyright: © 2010 Comunale et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grant R01 CA120206-01 from the National Cancer Institute (NCI), grant UO1 CA084951-06 from the NCI Early Research Detection Network (EDRN), the Hepatitis B Foundation, and an appropriation from The Commonwealth of Pennsylvania. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: anand.mehta@drexelmed.edu

Introduction

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is the major etiology of hepatocellular cancer (HCC) [1–4]. Both HBV and HCV cause acute and chronic liver infections, and most chronically infected individuals remain asymptomatic for many years [3]. About 10% to 40% of all chronic HBV carriers eventually develop liver cancer, and it is estimated that over one million people worldwide die because of HBV- and HCV-associated liver cancer [2,6,7]. Indeed, HBV and HCV infections are associated with over 80% of all cases of HCC worldwide and can be as high as 96% in regions where HBV is endemic [3].

The progression of liver disease to liver cancer is primarily monitored by serum levels of the oncofetal glycoprotein, alpha-fetoprotein (AFP), or the core fucosylated glycoform of AFP, AFP-L3. AFP can, however, be produced in many circumstances, including in relation to other liver diseases [8–10] and is not present in all those with HCC [11]. Therefore the use of AFP as a primary screen for HCC has been questioned [12], and more sensitive serum biomarkers for HCC are needed.

The glycosylation of proteins is cell specific. The N-linked glycosylation of a protein reflects modifications that occurred in the cell from which it came [13]. The glycosylation of the same protein secreted from diseased tissue, malignant cells or normal cells may, and often do, differ [14]. We, and others, have observed changes in N-linked glycosylation with the development of cirrhosis and HCC [15–19]. Specifically, the amount of core fucosylated N-linked glycan derived from total protein preparations isolated from the serum of individuals chronically infected with HCV and from those with a diagnosis of HCC was consistently greater than that in healthy patients or in those with HCV and “inactive” disease [19].

Using fucose-specific lectins to identify the proteins that become fucosylated in patients with liver disease, we identified more than 100 glycoproteins from patients with HCC and/or cirrhosis that contained increased fucosylation [19]. One of these proteins was
alpha-1-antitrypsin (A1AT). We analyzed the N-linked glycosyla-
tion of the five major isomers of A1AT and discovered, in
addition to increased levels of core fucosylation, significant
increases in outer arm fucosylation with the development of liver
cancer. Using a lectin-based assay, we measured this change in
over 400 patients with liver disease and found AAL reactive A1AT
could detect HCC with a sensitivity of 70% and a specificity of
86% using a cut-off of 5 relative units. Glycan analysis of the false
positives identified outer-arm fucosylation as being the cause of false
positivity. In contrast, increases in core fucosylation were found
only in patients with cancer. The reasons for this change
and the clinical usefulness of this change are discussed.

**Materials and Methods**

**Ethics Statement**

Both the Drexel University College of Medicine and the Saint
Louis University Institutional Review Boards approved the study
protocol, which was consistent with the standards established by
the Helsinki Declaration of 1975. Written informed consent was
obtained from each participant.

**Patients**

Serum samples were obtained from the Saint Louis University
School of Medicine (Saint Louis, MO). Demographic and clinical
information along with a blood sample was collected from each
participant in a serum separator tube. The sample was spun within
2 hours, and the serum was stored at −80°C until testing. Patients
were enrolled in the Saint Louis University Liver Cancer Clinic
and HCC were diagnosed using the same criteria established for
the HALT-C trial [20]. Participants had HCC identified by
biopsy, by a new hepatic defect showing vascular enhancement on
one imaging modality (ultrasound [US]), magnetic resonance
imaging [MRI], or computed tomography [CT]) with AFP levels
>1000 ng/ml or, by presumed HCC. Participants were presumed to
have HCC if they had a discrete hepatic defect on US with
AFP levels <1000 ng/ml and either two other scans (MRI, CT,
angiography) indicating malignancy with at least one of the following characteristic: hypervascularity, arterial to portal
vein shunts, portal vein thrombosis near the defect, tumor in the
portal vein, or one other scan (MRI or CT) showing features
characteristic of HCC and either an increase in size over time after
initial discovery (at least doubling if less than 1 cm) or an increase
in the level of AFP to >200 ng/ml. Tumor staging was deter-
mined using the United Network of Organ Sharing-modified
(UNOS) TNM staging system for HCC. For the cirrhosis group,
patients with hepatitis C and biopsy-proven cirrhosis were
enrolled. All cirrhotic controls were screened for HCC using
US, CT or MRI with AFP levels >1000 ng/ml and either two other scans (MRI, CT, angiography) indicating malignancy with at least one of the following characteristics: hypervascularity, arterial to portal
vein shunts, portal vein thrombosis near the defect, tumor in the
portal vein, or one other scan (MRI or CT) showing features
characteristic of HCC and either an increase in size over time after
initial discovery (at least doubling if less than 1 cm) or an increase
in the level of AFP to >200 ng/ml. Tumor staging was deter-
mined using the United Network of Organ Sharing-modified
(UNOS) TNM staging system for HCC. For the cirrhosis group,
patients with hepatitis C and biopsy-proven cirrhosis were
enrolled. All cirrhotic controls were screened for HCC using
US, CT or MRI prior to enrollment. Participants who were HBsAg+
(with or without HBV DNA were classified into the HBV group.
Similarly, patients who were HCV RNA positive, with no
evidence of cirrhosis, were classified into the HCV group. Patients
with other non viral liver disease but without cirrhosis were
classified into the other liver disease group (OLD). Control
patients were healthy patients recruited by the study to act as
controls.

**Two-Dimensional (2-D) Gel Electrophoresis**

A total of 7 μl of serum was diluted in 330 μl of solubilization
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 65 mM
DTT, 5 mM tributylphosphine, and a 0.4% mixture of carrier
ampholytes (Servalyt pH 2–4, pH 3–10, pH 9–1, 1:2:1). Samples
were vortexed periodically for 1 h and applied to an 18-cm pH
3–7 NL immobilized pH gradient (IPG) strip (Amersham,
Piscataway, NJ, USA). Gel rehydration was carried out for 14 h
at 50 V and focused using the IPGPhor (Amersham) isoelectric
focusing apparatus. After focusing, gel strips were first reduced
then alkylated in 6M urea, 2% SDS, 30% glycerol, 50 mM Tris,
pH 6.8, and either 30 mM DTT or 75 mM iodoacetamide for
10 min each. The second dimension was resolved with an 8% to
18% acrylamide–0.8% PDA gradient gel on a Protein II xi Cell
(BioRad Laboratories Headquarters, Hercules, CA, USA) with the
running conditions set to 20 mA/gel for 20 min and 40 mA/gel
for 4 h. Gels were fixed and stained with colloidal Coomassie. Gels
were imaged using the Odyssey Infrared Imaging System (Li-Cor
Biosystems, Lincoln, Nebraska) and analyzed using NonLinear
Dynamics Progenesis Workstation gel imaging software (NonLin-
ear Durham, NC, USA).

**Matrix-Assisted Laser Desorption/Ionization-Time-of
Flight (MALDI-TOF) Mass Spectrometry**

Protein spots were excised from colloidal Coomassie blue
stained gels, destained, and digested with trypsin. Recovered
peptides were concentrated and desalted using ZipTip C18
(Millipore, Bedford, MA, USA) according to the manufacturer’s
directions and prepared for MALDI-TOF mass spectrometry by
mixing 0.5 mL of peptide mixture with 0.5 mL of 10 mg/mL tr-
cyano-4-hydroxycinnamic acid and 1% formic acid in 50% acetonitrile and allowing the droplet to dry on the MALDI plate.
Peptide mass maps were obtained using a Voyager-DE Pro Mass
Spectrometer (Applied Biosystems, Life Biotechnologies, Carlsbad,
CA) operated in positive ion reflectron mode. Proteins were
identified from the peptide mass maps using the MASCOT online
database (www.matrixscience.com) to search the nonredundant
protein database.

**Glycan Analysis**

The 2DE gel spots were excised and destained using 40%
methanol 7% acetic acid. The gel plugs were dehydrated with
acetonitrile, the acetonitrile was removed and 25mM DTT was
allowed to absorb into the plug. The plug was heated to 100°C for
5 min, allowed to cool, and alkylated in the dark for 30 min with
75mM iodoacetamide. The gel plugs were washed using two
repeats of acetonitrile dehydration and 20 mM ammonium bicarbonate rehydration. After a final dehydration, the gel plugs
were dried in a speed vac. Peptide-N-glycosidase F (PNGase F) was
diluted with 20 mM ammonium bicarbonate pH 7 and allowed to
absorb into the gel plug. The gel plug was then covered with the
same solution and allowed to incubate overnight at 37°C. The
glycans were eluted from the gel plug by sonication in Milli-Q
water three times; the eluant was pooled, dried down, and labeled
with a 2AB dye (Ludger, Oxford, UK) according to the
manufacturer's instructions. The glycans were then cleaned up
using paper chromatography and filtered using a 0.22-μm syringe
filter. Fluorescently labeled glycans were subsequently analyzed
using the Waters Alliance high-performance liquid chromatogra-
phy system with a normal phase column (TSK amide 80 columns)
complemented with a Waters fluorescence detector and quantified
using the Millennium Chromatography Manager (Waters Corpora-
tion, Milford, MA). The mobile phase consisted of solvent A
(50 mM ammonium formate, pH 4.4) and solvent B (acetonitrile).
The gradient used was as follows: linear gradient from 20% to
58% solvent A at 0.4 mL/minute for 152 min followed by a linear
gradient from 38% to 100% solvent A for the next 3 min. The
flow rate was increased to 1.0 mL/minute; the column was
washed in 100% solvent A for 5 min. Following the wash step, the
column was equilibrated in 20% solvent A for 22 min in
preparation for the next sample. Glycan structures were identified
by calculating the glucose uptake value and exoglycosidase digestion, as described previously [21].

**Lectin-Fluorophore-linked Immunosorbent Assay (FLISA)**

The capture antibody (mouse antihuman A1AT, AbD Serotec, Raleigh NC, USA), was incubated with 10 mM sodium periodate for 1 h at 4°C. The treatment ensures the lectin is unable to react with the glycosylation of the antibody and does not affect antibody substrate binding. An equal volume of ethylene glycol was added, and the oxidized antibody was brought to a concentration of 10 μg/mL with sodium carbonate buffer, pH 9.5. Antibody (5 μg/well) was added to the plate and, following incubation, was washed with 0.1% Tween 20mM phosphate buffered saline pH 7.4. The plate was blocked overnight with 3% bovine serum albumen/phosphate buffered saline. For analysis, 5 μL of serum was diluted in 95 μL blocking reagent in Heterophilic Blocking Tubes™ (Scantibodies Laboratory, Inc. Santee, CA, USA) and was incubated at room temperature for 1 h. Subsequently, samples were added to the plates for 2 h and washed 5 times in lectin incubation buffer (10 mM Tris pH 8.0, 0.15M NaCl, 0.1% Tween 20). Fucosylated A1AT was detected with a biotin conjugated streptavidin; the signal intensity was measured using the Odyssey CA). Bound lectin was detected using IRDye 800 conjugated streptavidin. An equal volume of ethylene glycol was added, with the glycosylation of the antibody and does not affect antibody substrate binding. An equal volume of ethylene glycol was added, and the oxidized antibody was brought to a concentration of 10 μg/mL with sodium carbonate buffer, pH 9.5. Antibody (5 μg/well) was added to the plate and, following incubation, was washed with 0.1% Tween 20mM phosphate buffered saline pH 7.4. The plate was blocked overnight with 3% bovine serum albumen/phosphate buffered saline. For analysis, 5 μL of serum was diluted in 95 μL blocking reagent in Heterophilic Blocking Tubes™ (Scantibodies Laboratory, Inc. Santee, CA, USA) and was incubated at room temperature for 1 h. Subsequently, samples were added to the plates for 2 h and washed 5 times in lectin incubation buffer (10 mM Tris pH 8.0, 0.15M NaCl, 0.1% Tween 20). Fucosylated A1AT was detected with a biotin conjugated *Aleuria aurantia* lectin (AAL) (Vector Laboratories, Burlingame, CA). Bound lectin was detected using IRDye 800 conjugated streptavidin; the signal intensity was measured using the Odyssey infrared imaging system (LI-COR Biotechnology, Lincoln, Nebraska). In all cases, signal intensities were compared to those of signals detected with commercially purchased human serum (Sigma Chemicals). The lectin-FLISA detects the amount of fucosylation present on an equal quantity of molecules captured from each patient sample and is performed in a manner independent of the total amount of protein in any given patient.

**Statistical Analysis**

Descriptive statistics for staged patients were compared by scatter plots that included the outliers. All values were reported as mean values plus or minus the standard error unless otherwise stated. Because the data did not follow typical Gaussian distribution, a nonparametrical test (two-tailed, 95% confidence, Mann-Whitney test) was used to determine statistical difference between the groups. To determine the optimal cutoff value for each marker, the receiver operating characteristic curves were constructed using all possible cutoffs for each assay. The area under the receiver operating characteristic curve was constructed and compared as described previously. A two-tailed P value of 0.05 was used to determine statistical significance. All analyses were performed using GraphPad Prism (San Diego, CA, USA).

**Results**

**Levels of A1AT and Degree of Sialylation in Patients with Liver Cirrhosis and HCC**

Pooled sera from healthy patients (n = 20), patients with liver cirrhosis (n = 20) and patients with HCC with a background of cirrhosis (n = 20) were resolved via 2-D gel electrophoresis (2DE) (Table 1). Figure 1A shows a representative 2-DE of normal human serum and Figures 1B, 1C and 1D show a focus on the 5 isoforms (M1, M2, M4, M6, and M7) of A1AT from the three patient groups. Three major and two minor A1AT isoforms are commonly seen when human serum is isoelectrically focused and run on a 2-D gel [22,23] and these are not altered in the three patient groups. The A1AT concentrations in each patient group were comparable (Figures 1E–1G) and fell within normal serum concentrations. This result was confirmed by analyzing A1AT an Enzyme-linked immunosorbent assay (ELISA), whereby the A1AT levels were 3.2 mg/mL in the composite from the healthy patients, 3.3 mg/mL in the composite from the cirrhotic patients, and 3.3 mg/mL in the composite from the HCC patients.

We performed glycan analysis on the M1, M2, M4, M6, and M7 isoforms from the pools of sera from normal participants and cirrhotic and HCC patients (Figures 1B–1D) and examined the sialylation patterns of each isotype. Figure S1 shows a representative glycan profile for the M4 isotype from the controls. Consistent with results of previous studies [24], the biantennary glycan is the most abundant species. Figure S1–B shows the level of the sialylated biantennary and triantennary glycan associated with each isoform from each patient group. As S1–B shows, the level of sialylation on the bi-antennary glycan (A2G2S1 or A2G2S2) was

### Table 1. Patients Utilized in Study.

| Disease Diagnosis¹ | HCC² | Cirrhosis³ | HBV⁴ | HCV⁵ | OLD⁶ | Controls⁷ |
|------------------|------|-----------|------|------|------|-----------|
| Number           | 63   | 65        | 33   | 215  | 62   | 20        |
| Etiology% (HBV/HCV/crypto/other)⁸   | 14/52/6/20/8 | N/A | N/A | 0/0/15/69 | N/A |
| Age              | 58.0±4.1 | 50±8     | 58.6±12 | 58±3 | 51±3 | 55±8     |
| Gender M/F%      | 71:29 | 84:16     | 75:25  | 60:40 | 56:44 | 50:50    |
| MELD Score⁹      | 11.8±5 | N/A       | N/A   | 9±2  | N/A  | N/A      |
| Child Class (A/B/C/) or NA%¹⁰ | 52:29:9:10 | 88:8:4 | N/A  | N/A | N/A  | N/A      |
| Tumor Stage (1/2/3/4) %¹¹ | 26:48:12:14 | NA | NA | NA | NA | NA      |

¹Samples were provided coded from St. Louis University Medical School.

²HCC or cirrhosis was determined by MRI or by liver biopsy.

³Patients classified as HBV only were defined as those with HBsAg positivity but no evidence of liver cirrhosis.

⁴Patients classified as HCV only were defined as those with HCV RNA positivity but no evidence of liver cirrhosis.

⁵OLD, including cryptogenic liver disease, alcohol induced liver disease, nonalcoholic steatohepatitis, and autoimmune hepatitis.

⁶Patients without any evidence of liver disease were used as controls.

⁷Etiology: HBV, hepatitis B virus; HCV, hepatitis C virus; crypto, cryptogenic liver disease; alcohol, alcohol induced liver disease; other, liver disease of unknown origin.

⁸MELD: Model for end stage liver disease.

⁹The percent of patients with each Child-Pugh score is given as a percentage in each group.

¹°Tumor staging was determined using the United Network of Organ Sharing-modified TNM staging system for HCC. The percent of patients within each stage is given. NA, not available.

HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MELD, model for end stage liver disease; OLD, other liver disease.

doi:10.1371/journal.pone.0012419.t001
observed on A1AT from patients with HCC. Increased levels of core and outer arm fucosylation are similar in the different patient groups. Similarly, the level of sialylation was not altered on the triantennary glycan. However, there was an increase in the level of the tri-sialylated glycan, but sialylation was not altered on the triantennary glycan. However, similar in the different patient groups. Similarly, the level of sialylation was not altered on the triantennary glycan. However, there was an increase in the level of the tri-sialylated core and outer arm fucosylation (A3F(3)1G3S3) on A1AT from the cancer patients, as compared to the healthy and cirrhotic patients. These peaks are indicated in figure S1A & B with an asterisk.

Increased Levels of Core and Outer Arm Fucosylation Are Observed on A1AT from Patients with HCC

To test if the increased level of tri-sialylated A1AT increased fucosylation in the outer arm of fucosylated A1AT (A3F(3)1G3), it was the result of an increase in sialylation or an increase in the total amount of parent glycan, sialic acid was removed enzymatically and the sample re-analyzed. Figure 2 shows the simplified desialylated glycoprofile of the five major isoforms for each of patient group following treatment with neuraminidase (Arthrobacter ureafaciens). Three peaks of interest, indicated with a star in Figure 2, are reproducibly altered in the M1, M2, and M4 isoforms as the disease progresses from cirrhosis to cancer. Sequential exoglycosidase digestion (data not shown) showed these peaks to be a core fucosylated biantennary glycan (F6/A2G2), a biantennary glycan (A3G3), and a triantennary glycan with a single A1AT isoform with very little tri- and tetra-antennary structures, the biantennary core fucosylated outer arm fucose residue (A3F(3)1G3). Figure 3A shows a representative desialylated profile with the corresponding glycan structure identified for each peak. Table 2 is a quantitation of each glycan structure present on the five major isoforms for each patient group. Specific changes in glycosylation are observed in the A1AT isoforms with the progression to cirrhosis and HCC. On M6, the isoform with very little tri and tetra-antennary structures, the biantennary core fucosylated glycan (F6/A2G2), represents 4.48% in normal patients, 4.37% in patients with cirrhosis, and 7.04% in patients with cancer, a trend seen across each isoforms (Table 2, glycan 6). The percent change between healthy and cirrhosis and between cirrhosis and cancer is given in Figure 3C and shows that this structure changes with the stage of HCC. The increase in outer arm fucosylation was also associated with a decrease in the parent N-linked glycan. That is, the increase in the outer arm fucosylated triantennary glycan, A3F(3)1G3, was associated with a decrease in triantennary glycan A3G3. (Table 2, glycan 6).

Analysis of Fucosylated A1AT by Lectin-FLISA in a Cohort of 458 Patients

To further examine if the changes in both core and outer arm fucosylation could be seen in individual patients and potentially used as a diagnostic marker of cancer, we analyzed a patient cohort consisting of 458 patients for the level of fucosylated A1AT using a lectin-FLISA based assay. In this assay, A1AT was captured using a monoclonal antibody and the level of fucosylation was determined using the fucose-binding AAL. AAL recognizes both outer arm and core fucosylated glycan. Twenty patients with no evidence of liver disease were used as controls; 33 patients infected with HBV had an unknown level of liver fibrosis; 215 patients infected with HCV had an unknown level of liver fibrosis; 65 patients had liver cirrhosis; 62 patients had other liver diseases; and 63 patients had liver cancer (Table 1). Figure 3A shows the relative level of fucosyl lectin-reactive A1AT in the six patient groups. Values are given as -fold increase in relation to the level in commercially purchased “normal” sera. The mean and 95% confidence interval of the mean are shown for each group. We found a clear statistical difference between the HCC group and all other groups (P<0.0001) and between the cirrhotic group and the control group (P<0.0173) but not between any other groups (Figure 3A). The mean level of lectin-reactive A1AT was 1.4-fold (±0.80) above sigma in the control group, 1.7-fold (±0.1.8) in the group infected with HBV, 1.9-fold (±1.8) in the group infected with HCV, 2.6-fold (±2.3) in the group with cirrhosis, 2.6-fold (±2.0) in the group with other liver diseases, and 7.7-fold (±4.45) in the group with HCC. Surprisingly, there was no difference in the mean level of AAL-reactive A1AT in HCC patients in regards to the stage of HCC (data not shown). That is patients with stage 1 HCC, as defined as a single lesion of less than 2cm [11], had a 9.1 fold (±4.70) increase in the level of AAL reactive A1AT while...
Figure 2. The desialylated N-linked glycan profile for each of the five A1AT isoforms from normal controls (top) and cirrhotic (middle) or HCC patients (bottom). The major peaks that are altered are indicated with an asterisk and are (from left to right) a core fucosylated bianntennary glycan (F96A2G2), a triantennary N-linked glycan, and a triantennary N-linked glycan with a single outer arm fucose residue (A3F[3]3). The percent of each of these peaks in the different isoforms and in the different patient groups is shown in Table 2.

doi:10.1371/journal.pone.0012419.g002

Figure 3. Specific changes in glycosylation on A1AT can be observed with the progression from liver cirrhosis to liver cancer. (A) A representative N-linked glycan profile from a normal control patient. The 11 major glycan structures identified are indicated and given a number. This number is used in Table 2 with structure names provided. The relative change in the level of the triantennary N-linked glycan with a single outer arm fucose residue (A3F[3]3G3) (B) and the core fucosylated bianntennary glycan (F6A2G2) (C) in normal to cirrhotic and cirrhotic to HCC is shown as percent change. As this figure shows, increases in outer arm fucosylation are associated with both cirrhosis and HCC, whereas increased core fucosylation is only observed with HCC.

doi:10.1371/journal.pone.0012419.g003
### Table 2. The N-linked Glycans Found on A1AT Isoforms from Controls, Patients with Cirrhosis, or Patients with HCC.

| Glycan # | Glycan Structure | M1 Healthy | M1 Cirrhosis | M1 HCC | M2 Healthy | M2 Cirrhosis | M2 HCC | M4 Healthy | M4 Cirrhosis | M4 HCC | M6 Healthy | M6 Cirrhosis | M6 HCC | M7 Healthy | M7 Cirrhosis | M7 HCC |
|----------|------------------|------------|--------------|--------|------------|--------------|--------|------------|--------------|--------|------------|--------------|--------|------------|--------------|--------|------------|--------------|--------|
| 1        | A2G2             | 65.30      | 57.37        | 53.16  | 63.49      | 59.12        | 57.90  | 66.39      | 62.55        | 89.73  | 88.29      | 80.87        | 73.64  | 71.70      | 75.60        |        |
| 2        | A2BG2            | 1.85       | 0.69         | 0.95   | 2.14       | 1.21         | 1.44   | 1.63       | 1.52         | 1.83   | 1.16       | 1.28         | 2.17   | 1.17       | 1.25         | 0.80   |
| 3        | F(6)A2G2         | 4.05       | 2.89         | 6.09   | 2.19       | 3.73         | 5.54   | 3.62       | 3.47         | 5.30   | 4.48       | 4.37         | 7.04   | 4.62       | 5.11         | 7.36   |
| 4        | A3F(3)1G(4)1     | 0.72       | 0.88         | 2.55   | 0.54       | 0.87         | 2.29   | 0.69       | 0.82         | 2.73   | 1.18       | 1.77         | 3.88   | 1.38       | 1.12         | 0.78   |
| 5        | A3G(4,3,4)3      | 0.78       | 0.60         | 0.00   | 0.00       | 0.00         | 0.00   | 0.00       | 0.00         | 2.77   | 2.12       | 2.40         | 1.57   | 2.15       | 3.44         |        |
| 6        | A3G3             | 18.70      | 15.44        | 9.62   | 19.26      | 12.72        | 7.65   | 19.83      | 16.29        | 8.65   | 0.28       | 0.65         | 0.69   | 13.04      | 10.13        | 4.74   |
| 7        | F(6)A3G3         | 1.15       | 0.93         | 0.81   | 1.02       | 0.72         | 0.84   | 1.08       | 0.69         | 0.91   | 0.00       | 0.00         | 0.00   | 0.71       | 0.90         | 0.36   |
| 8        | A3F(3)1G3        | 3.39       | 6.08         | 13.18  | 3.73       | 4.97         | 11.04  | 4.34       | 6.78         | 13.18  | 0.00       | 0.00         | 0.00   | 2.62       | 4.39         | 5.98   |
| 9        | A4G4             | 2.38       | 7.27         | 2.52   | 4.34       | 7.85         | 2.41   | 0.54       | 0.88         | 0.55   | 0.00       | 0.00         | 0.00   | 0.00       | 0.00         | 0.00   |
| 10       | A4F(3)1G(4)4     | 0.00       | 2.34         | 2.93   | 0.66       | 2.54         | 2.53   | 0.00       | 0.00         | 0.45   | 0.00       | 0.00         | 0.00   | 0.00       | 0.00         | 0.00   |
| 11       | F(6)A4F(3)1G(4)4 | 0.00       | 1.22         | 2.78   | 0.00       | 1.46         | 2.27   | 0.00       | 0.00         | 0.00   | 0.00       | 0.00         | 0.00   | 0.00       | 0.00         | 0.00   |

1. A1AT isoforms as shown in Figure 1.
2. Peak number as shown in Figure 3.
3. Glycan structure as determined by exoglycosidase digestion. See text and figure 3 for more detail.
4. The percent that each glycan structure represents in the total glycan profile. The total does not equal 100% because certain minor peaks were not identified and did not alter in the patient groups.

doi:10.1371/journal.pone.0012419.t002
patients with stage 4 HCC (those with multiple lesions $>6\text{cm}$ in diameter) had a mean of 6.7 fold ($\pm 5.54$), which was not different than that observed in stage 1 patients ($p = 0.114$).

In this cohort, fucosylated A1AT could distinguish between HCC and non-HCC cases with an area under the receiver operator curve (AUROC) of 0.671. When comparing only HCC versus cirrhosis, the discriminatory ability was 0.867. Using a cut-off of 5 relative units AAL reactive A1AT could differentiate HCC from cirrhosis with a sensitivity of 70% and a specificity of 86%. In contrast, AFP, when analyzed in this cohort, had an AUROC of 0.764 and could differentiate HCC from cirrhosis with a sensitivity of 59% and a specificity of 93% using a cut-off of 20 ng/mL.

**False Positives Have Increased Levels of Outer Arm Fucosylation Whereas Core Fucosylation Is Specific for HCC**

Some patients do not have cancer but have elevated levels of lectin-reactive A1AT (Figure 4A). Because we observed changes in outer arm fucosylation on A1AT from patients with cirrhosis, it was of interest to determine if those with false positive results had core or outer arm fucosylation. Figure 4A shows the results of glycan analysis from purified A1AT from three cirrhotic patients (out of nine) and three patients with stage 1 or 2 HCC (out of nine) and analyzed as before. The results from these patients are shown in Figure 4A, and a representative glycan profile of one of these patients is shown in Figure 4B, along with the level of 4 major glycan structures indicated. As Figure 4B shows, consistent with the results presented in Table 2 and in Figures 3A–3C, the three cirrhotic patients have levels of core fucosylation (F(6)A2G2) similar to those observed in healthy controls. However, these patients have significant increases in outer arm fucosylation (A3F(3)1G3), similar to the highest levels seen in patients with HCC. That is, the level of outer arm fucosylation in these patients ranged from 10% to 17%, which is similar to the level observed in patients with HCC (13%). In contrast, three patients with HCC who had very strong positive results from the lectin FLISA test had increased core and outer arm fucosylation. For example, the core fucosylated biamnentary glycan represented 9.55% on A1AT purified from patient H27. Similarly, this glycan represented more than 9% on A1AT purified from patients H18 and H23. Increases in outer arm fucosylation ranging from 14.03% to 15.97% of the total glycan on A1AT were also observed in these patients. Figure 4D shows the results of all 18 patients with a focus on the level of outer arm ($\alpha$-1,3) and core ($\alpha$-1,6) fucosylation. When examining all 9 cirrhotic false positives the mean level of core fucosylation was 3.77%±0.25 and the mean level of outer arm fucosylation was 11.88%±2.79. In the case of the cancers the mean level of core fucosylation was 8.62%±1.2 and the mean level of outer arm fucosylation was 14.26%±1.9. There was statistical difference between the level of core $\alpha$-1,6 fucosylation between these nine cirrhotic and nine HCC patients ($p<0.0001$) but not with $\alpha$-1,3 linked fucosylation ($p = 0.07$). Importantly, the maximum level of core fucosylation observed in the false positive cirrhotics was 4.01%, similar to what was observed in healthy controls (3.62%).

Figure 4. Increase in lectin-reactive A1AT with the development of HCC and identification of core fucose as a specific marker of liver cancer. (A) The level of lectin-reactive A1AT in patients with HCC, HBV infection, HCV infection, or other liver diseases (OLD) and in controls. The solid line represents the mean value. The $x$-axis represents the patient group. The $y$-axis shows the fold increase in lectin-reactive A1AT compared with that in commercially purchased serum. (B) Glycan analysis of A1AT isoform M4 from patient 21. (C) Quantification of glycan analysis from three cirrhotic patients (01,21 and 27) and three patients with stage 1 or 2 HCC (HCC-23, HCC 27 and HCC 18). The levels of 4 major glycan structures are shown. As this figure shows, in cirrhotic false positives, there is an increase in outer arm but not core fucosylation. Consistent with data shown in Figures 2 and 3, increases in core fucosylation on AAT were observed only from patients with HCC. (D) Scatter plot of the level of $\alpha$-1,3 or $\alpha$ 1,6 linked fucose from 9 cirrhotic false positives and 9 patients with either stage 1 or 2 HCC.

doi:10.1371/journal.pone.0012419.g004
Discussion

Recent reports have indicated that increased core and outer-arm fucosylation could be observed following glycomic analysis of either total human serum or serum depleted of immunoglobulin [18,19,25]. We examined the glycosylation of a single protein, A1AT, as a function of liver cirrhosis and liver cancer. To this end, we found some changes that were consistent with our previous findings such as an increase in core fucosylation as well as changes in outer arm fucosylation.

The observation that changes in both core and outer arm fucosylation occur may provide clues to the molecular basis of this change. That is, although the exact mechanisms for increased core fucosylation in HCC are unknown, they are thought to involve increases in both the levels of the enzyme and the substrates involved in core fucosylation.

It is also possible that these markers reflect some alteration in the Golgi apparatus. Recent reports have suggested that, in regard to the liver, the fucosylation of proteins is involved in protein sorting to the bile [26]. Thus, it is conceivable that the appearance of fucosylated proteins in the serum may reflect a common defect in protein sorting. It is interesting to note that the glycosylation of A1AT in the serum of patients with liver cancer (Figures 2, 3 and 4) is similar to that observed in the bile of healthy individuals [26].

It is also interesting to note that lectin reactivity was greater than the total change observed in fucosylation. For example, patient 27 had either core or outer arm fucose on 22.82% of his or her N-linked glycans. In contrast, A1AT from a healthy individual had fucose (core or outer arm) on 9% of the N-linked glycans. Hence, using the lectin FLISA, we should have observed closer to a 2.5-fold increase and not the 11-fold increase that was obtained. This difference may be an artifact of the lectin-FLISA, the result of other proteins attached to A1AT, increased or modified O-glycosylation, or increased accessibility of the lectin to the fucose residues. All of these possible scenarios are under investigation.

It is also important to note that increased outer arm fucosylation was observed both in patients with cirrhosis and in those with HCC. This finding implies that outer arm fucosylation was not specific to cancer but rather was probably associated with inflammation, first from the liver cirrhosis and then from the presence of the HCC lesion. Indeed, the level of outer arm fucosylation may be a more specific marker of inflammation and may be predictive of cancer development [27,28]. In contrast, increases in core fucosylation are observed only in patients with HCC, suggesting that this change is cancer specific.

As Figure 4A shows, many patients in the non-HCC groups have elevated levels of lectin-reactive AAL. Analysis of three patients with elevated AAL levels from the cirrhosis group indicated that they had changes primarily in outer arm fucosylation, not in core fucosylation. To that end, core fucosylation may be a more specific target for the detection of cancer [29]. Efforts to use lectins such as lens culinaris and Pisum sativum agglutinin, which will not bind outer arm fucosylated glycan, in the lectin FLISA proved problematic because these lectins have much weaker binding affinities and do not actually bind fucose directly. Efforts to make recombinant AAL with specificity only to core-linked α-1,6 fucose are currently underway.

In summary, we have analyzed the glycosylation of A1AT as a function of HCC and used a lectin FLISA to measure this change in a cohort of more than 400 patients. These data need to be confirmed in larger cohorts of patients to determine if these markers are truly reliable serum markers of early HCC, to compare their accuracy with AFP in patients of diverse gender, ethnicity, etiologies of liver disease, and to determine their role in HCC surveillance. Future studies should also test the benefit of combinatorial analysis with other potential markers of HCC, such as des-gamma-carboxy prothrombin as well as to examine how the level of core and outer arm fucosylation varies as a function of anti-cancer treatment.

Supporting Information

Figure S1 The sialylated N-linked glycan profile for each of the five A1AT isoforms from normal, cirrhotic, or HCC patients. (A) A representative sialylated profile of the M4 A1AT isoform from healthy individuals. (B) The relative percent of sialylated bi-antennary or tri-antennary glycan in each A1AT isoform. Found at: doi:10.1371/journal.pone.0012419.s001 (3.00 MB TIF)

Author Contributions

Conceived and designed the experiments: MAC AM. Performed the experiments: MAC LRB JH MW AM. Analyzed the data: MAC MW PN AMDR TB AM. Contributed reagents/materials/analysis tools: AMDR AM. Wrote the paper: MAC AM.

References

1. Di Biaseglie AM (1989) Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection. Med Clin North Am 73: 985–997.
2. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22: 5093–5107.
3. Marrero JA (2006) Hepatocellular carcinoma. Curr Opin Gastroenterol 22: 248–253.
4. Sallie R, Di Biaseglie AM (1994) Viral hepatitis and hepatitis C. Critical Care Clin North Am 20: 367–379.
5. Lok A, McMahon B (2001) Chronic hepatitis B. Hepatology 34: 1225–1241.
6. El Serag HB, Mason AC, Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33: 62–65.
7. Srbulah AA, Gramlich T, Younossi Z, Osmack P, Goormastic M, et al. (2004) Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 49: 850–853.
8. Alpert ME, Ureil J, de Nechaud B (1968) alpha fetoglobulin in the diagnosis of human hepatoma. N Engl J Med 278: 904–908.
9. Ruohola H, Salaspuro M, Pihko H, Anderson L, Soppera M (1974) Serum alpha-fetoprotein: diagnostic significance in liver disease. Br Med J 2: 527–529.
10. Di Biaseglie AM, Hoofnagle JH (1989) Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 64: 2117–2120.
11. Marrero JA, Romano PR, Nikolaeva O, Stool L, Mehta A, et al. (2005) GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43: 1007–1012.
12. Sherman M (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 145–154.
13. Rudd PM, Dwek RA (1997) Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 32: 1–100.
14. Aoyagi Y, Suzuki Y, Igashita K, Yokota T, Mori S, et al. (1993) Highly enhanced fucosylation of alpha-fetoprotein in patients with germ cell tumor. Cancer 72: 615–618.
15. Naitoh A, Aoyagi Y, Asakura H (1999) Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 14: 436–445.
16. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, et al. (1998) The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 83: 2076–2082.
17. Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, et al. (2003) Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res 63: 6282–6289.
18. Block TM, Comunale MA, Lownan M, Steel LF, Romano PR, et al. (2005) Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 102: 779–784.
19. Comunale MA, Lownan M, Long RE, Krokover J, Philip R, Seelhorzer S, Evans AA, Hamm HWL, Block TM, Mehta AS (2006) Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. Journal of Proteome Research 6: 308–315.

HCC Glycosylation

PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12419
20. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429–2441.

21. Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA (1996) A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 240: 210–226.

22. Jeppsson JO, Einarsson R (1992) Genetic variants of alpha 1-antitrypsin and hemoglobin typed by isoelectric focusing in preselected narrow pH gradients with PhastSystem. Clin Chem 38: 577–580.

23. Brooks KP, Iammarino RM (1985) Determination of alpha-1-antitrypsin phenotypes and M subtypes by isoelectric focusing in immobilized pH gradients. Clin Biochem 18: 280–284.

24. Kolarich D, Weber A, Turecek PL, Schwarz HP, Altmann F (2006) Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms. Proteomics 6: 3369–3380.

25. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, et al. (2007) N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46: 1426–1435.

26. Nakagawa T, Uozumi N, Nakano M, Minuno-Horikawa Y, Okuyama N, et al. (2006) Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 281: 29797–29806.

27. Abd Hamid UM, Royle L, Saldova R, Radcliffe GM, Harvey DJ, et al. (2008) A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 18: 1105–1118.

28. Arnold JN, Saldova R, Hamid UM, Rudd PM (2008) Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8: 3284–3293.

29. Peracaula R, Sarrats A, Saldova R, Pla E, Fort E, et al. (2010) Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. PROTEOMICS - Clinical Applications In press.